Pharmaceutical Business review

Tianyin to expand formulation for GMOL

GMOL is used in China to treat brain ischemia and infarction, coronary heart diseases, memory dysfunction and other neurological disorders.

Gingko extracts mainly comprise flavonoids and terpenoids.

Flavonoids consist of ginkgoflavone glycoside which are antioxidants that reduce capillary fragility observed in cardiovascular disorders.

Terpenoids consist of ginkgolides and bilobalide that inhibit platelet activating factor (PAF) which in consequence reduce the blood viscosity.

GMOL also contains extracts from Gastrodia elata for treating neurological symptoms like epilepsy, headaches, dizziness and memory dysfunction.

According to the company, the new capsule formulation will reduce the overall cost of sales by 70% while extending the expiration period to 3 years from the existing 2 years.